157 related articles for article (PubMed ID: 15283313)
21. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF; Curran MP; Goa KL; Perry CM
Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
[TBL] [Abstract][Full Text] [Related]
22. Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.
Palmer AJ; Valentine WJ; Ray JA; Roze S; Muszbek N
Eur J Health Econ; 2007 Jun; 8(2):161-8. PubMed ID: 17237927
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.
Gialama F; Maniadakis N
Vasc Health Risk Manag; 2013; 9():575-92. PubMed ID: 24124375
[TBL] [Abstract][Full Text] [Related]
24. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
[TBL] [Abstract][Full Text] [Related]
25. [Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus].
Belousov IuB; Shestakova MV; Belousov DIu
Kardiologiia; 2008; 48(12):14-9. PubMed ID: 19076089
[TBL] [Abstract][Full Text] [Related]
26. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Evans M; Bain SC; Hogan S; Bilous RW;
Nephrol Dial Transplant; 2012 Jun; 27(6):2255-63. PubMed ID: 22172728
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Delea TE; Sofrygin O; Palmer JL; Lau H; Munk VC; Sung J; Charney A; Parving HH; Sullivan SD
J Am Soc Nephrol; 2009 Oct; 20(10):2205-13. PubMed ID: 19762496
[TBL] [Abstract][Full Text] [Related]
28. Pharmacoeconomic challenges in the management of diabetic nephropathy.
Rodby RA
J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S6-11. PubMed ID: 15369419
[TBL] [Abstract][Full Text] [Related]
29. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
[TBL] [Abstract][Full Text] [Related]
30. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Ruilope LM; Segura J
Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
[TBL] [Abstract][Full Text] [Related]
31. [Health economic aspects of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Schute LL
Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1448; author reply 1448. PubMed ID: 15213879
[No Abstract] [Full Text] [Related]
32. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes.
Palmer AJ; Chen R; Valentine WJ; Roze S; Bregman B; Mehin N; Gabriel S
Diabetes Metab; 2006 Feb; 32(1):69-76. PubMed ID: 16523189
[TBL] [Abstract][Full Text] [Related]
33. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Pohl MA; Blumenthal S; Cordonnier DJ; De Alvaro F; Deferrari G; Eisner G; Esmatjes E; Gilbert RE; Hunsicker LG; de Faria JB; Mangili R; Moore J; Reisin E; Ritz E; Schernthaner G; Spitalewitz S; Tindall H; Rodby RA; Lewis EJ
J Am Soc Nephrol; 2005 Oct; 16(10):3027-37. PubMed ID: 16120823
[TBL] [Abstract][Full Text] [Related]
34. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.
Maniadakis N; Ekman M; Fragoulakis V; Papagiannopoulou V; Yfantopoulos J
Eur J Health Econ; 2011 Jun; 12(3):253-61. PubMed ID: 20411401
[TBL] [Abstract][Full Text] [Related]
35. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
Ekman M; Bienfait-Beuzon C; Jackson J
J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
38. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
[TBL] [Abstract][Full Text] [Related]
39. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
[TBL] [Abstract][Full Text] [Related]
40. A clinical trial in type 2 diabetic nephropathy.
Lewis EJ; Hunsicker LG; Rodby RA;
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S191-4. PubMed ID: 11576953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
